T
he role of antibody immunity in resistance to particular pathogens is frequently determined by correlating the presence of specific antibody with resistance to infection. However, the polyclonal antibody response that is elicited by both vaccination and infection consists of a complex mixture of antibodies differing in isotype, epitope specificity, and protective efficacy. The interpretation of experiments using polyclonal preparations is further complicated by the fact that nonprotective antibodies have been shown to block the activity of protective antibodies in some bacterial infections (1) (2) (3) (4) . Blocking activity may be due to direct competition for the binding of the same or closely related epitopes (1, 5) or to the enhancement of infection by nonprotective antibodies through a variety of mechanisms (2, 6) . This suggests that the relative amounts of protective and nonprotective antibodies elicited by infection or immunization can determine the outcome of infection. Passive administration of mAbs individually and in combination can reveal the impact of nonprotective antibodies on the polyclonal response.
Although it is generally accepted that antibodies contribute to resistance to viruses and bacteria, the role ofantibod-G. Nussbaum and R.R. Yuan contributed equally to this work. ies in fungal infections is controversial and poorly understood (7) . Many of the studies supporting or contradicting antibody efficacy against medically important fungi based their conclusions on data obtained using polyclonal sera. The amount of specific antibody, the isotype composition, and the epitope specificity of the specific antibodies in the polyclonal preparations used in these studies varied and may not have been sufficient to mediate protection. When mAbs were used, protective and nonprotective antibodies were identified to Cryptococcus neoformans and Candida albicans (7, 8) .
The difficulty in treating cryptococcal infections has renewed interest in the therapeutic potential of antibody immunity. C. neoformans causes a life-threatening meningoencephalitis in 6-8% of patients with AIDS that is usually incurable despite antifungal therapy (9) . The large polysaccharide capsule surrounding C. neoformans distinguishes it from other fungal pathogens and is a major determinant of virulence (10) (11) (12) (13) . Although protective antibodies could be useful therapeutically, nonprotective (14) and even enhancing (15) mAbs to cryptococcus have also been described, raising the possibility that such antibodies could interfere with the efficacy of the protective antibodies and increase susceptibility to infection. In this study we tested the impact of nonprotective IgG3 mAbs on the ability of mAbs of the IgG1 and IgG2a isotypes to modulate cryptococcal infection in the mouse. Our results indicate that rather than being simply ineffective, IgG3 antibodies reduce the protection provided by the IgG1 and IgG2a isotypes. Ascites Preparation. Ascites was generated by injecting 10 7 hybridoma cells into the peritoneal cavity ofpristane-primed BALB/c mice. Antibody concentration was determined by ELISA relative to isotype-matched standards of known concentration. Although 4H3 is an IgG3h mAb, the 4H3 hybridoma produces a small percentage of antibody with K light chains (17) , and the K chain containing antibodies was removed by absorbing the ascites three times on a rat anti-mouse K Sepharose 4B column (Zymed Laboratories Inc., South San Francisco, CA).
Materials and Methods
Animal Experiments. Female A/J mice ages 6-8 wk were used for protection experiments. Mice were obtained from the National Cancer Institute (Rockville, MD) for the intravenous infection experiments and from The Jackson Laboratory (Bar Harbor, ME) for the intraperitoneal experiment, based on availability. A/J mice were chosen because they are highly susceptible to infection with C. neoformans (18) . Protection experiments were performed as described (19, 20) . C. neoformans was administered intravenously through the tail vein or by intraperitoneal injection. mAb was administered intraperitoneally either 24 h before infection in the case of intravenous challenge, or ~30 min before infection in the case of intraperitoneal challenge. The dose of each mAb was 1 mg. Animals who received two antibodies received a total of 2 mg mAb mixed before challenge. The cryptococcal inoculum was 2 • 106 cells/mouse in the case of intravenous infection and 108 cells/mouse in the case of intraperitoneal infection. Deaths were recorded daily.
Statistics. Survival data were analyzed by the Mann-Whitney test using statistical software for the Macintosh (Instat version 2.01; GraphPAD Software for Science, San Diego, CA).
Results

Effect of IgG3 on a Protective IgG1 with Identical Specifidty.
In previous studies, we demonstrated that 3E5 IgG3 mAb did not protect mice from lethal infection with C. neoformans (15, 19) . When 3E5 IgG3 was switched to the IgG1 isotype, it prolonged survival and reduced tissue fungal burden (15) . mAb 3E5 IgG3 and its 3E5 IgG1 switch variant have identical variable regions but differ in isotype (15) .
To determine the effect of 3E5 IgGl and 3E5 IgG3 in combination, 1 mg of each antibody was given alone or in combination to groups of five mice 24 h before intravenous infection with 2 • 106 cryptococci. Consistent with previous results (15), 3E5 IgG3 did not prolong survival compared with saline controls (P = 0.249), whereas the IgG1 switch variant did (P = 0.0002, Fig. 1 ). Mice who received 1 mg each of IgG1 and IgG3 were still protected compared with the PBS control group (P = 0.0085); however, protection was significantly reduced compared with mice receiving the IgG1 alone (P = 0.0052). ficity reduced the efficacy of an IgG1 mAb when they were administered simultaneously in routine intravenous infection.
Effect of lgG3 on a Protective IgG2a. IgG3 mAb A2F12
and IgG2a mAb 7F8 were recovered from splenic fusions of different NZB/W mice immunized with GXM-PsA (Nussbaum, G., et al., manuscript in preparation). For protection experiments, groups of mice were given 1 mg of each mAb alone or in combination before intraperitoneal challenge with 108 cryptococci. The IgG2a mAb 7F8 alone conferred significant protection (P = 0.0001, Fig. 3 ) and, as with some of our other IgG3 nLAbs, A2F12 was minimally protective (P = 0.0357). Animals who received 1 mg each of 7F8 and A2F12 died faster than those who received 7F8 alone (P = 0.0172) but survived longer than the group who received A2F12 alone (P = 0.001). Thus an IgG3 mAb reduced the protective efficacy of an IgG2a mAb in a murine model ofintraperitoneal infection.
Discussion
Three different IgG3 mAbs to GXM were studied, and all reduced the efficacy of protective GXM-binding mAbs. In the first case, we used 3E5 IgG3 and IgG1 isotype switch variants that bind to the same epitope (15) . The IgG3 was ineffectual when administered alone and reduced survival provided by IgG1. Since these antibodies may compete for binding to the surface of the organism, the nonprotective IgG3, which binds with higher avidi W (15) because of cooperative IgG3 Fc-Fc interactions (21, 22) , may block effective opsonization by IgG1. We therefore tested IgG3 and IgG1 antibodies that use different H and L chain variable region genes, bind different epitopes on the cryptococcal capsule (19, 23) , and do not compete by ELISA. In this case, the 4H3 IgG3 alone enhances cryptococcal infection. When administered together with IgG1, 4H3 IgG3 abolished the 3E5 IgG1 mediated protection. Finally, we mixed an IgG3 that was minimally protective when given alone with a highly protective IgG2a in a different model of infection. These antibodies use the same variable region genes but have unique somatic mutations that may or may not confer differences in fine specifici W. In this experiment, the IgG3 again reduced protection provided by IgG2a.
To our knowledge, this is the first report of blocking antibodies to a fungal pathogen. The term blocking antibodies describes nonbactericidal antibodies that prevent killing by bactericidal antibodies or complement in a wide range of gram-negative organisms. Antibodies that are unable to fix complement effectively or to promote phagocytosis may prevent protective antibodies from binding by competition for the same epitope, or by steric hindrance when they bind to different, but closely located, epitopes. For example, IgG antibodies to the outer membrane protein PIII of Neisseria gonococcus block bactericidal antibody binding to PI and fix complement on sites that do not lead to bacterial death (1, 6, 24) . Human convalescent gonococcal and meningococcal antisera can effectively block the natural bactericidal activity of normal serum (1, 2, 5) , and preexisting antibody to gonococcal PIII facilitates gonococcal transmission (24, 25) . Human IgA1 against N. meningitides blocks IgG bactericidal activity when both are directed against distinct polysaccharide epitopes (2). In Dengue virus infection, virus-reactive antibody enhances cel/ular infection in vitro (26) and in vivo (27) , and severe disease (Dengue shock syndrome and Dengue hemorrhagic fever) occurs most often in patients with a preexisting low level of IgG antibody (for review see reference 28). Nonneutraliz-ing antibodies against viruses (29) or nonopsonic antibodies against bacteria (30) in general may interfere with the bivalent binding of protective antibodies and may explain why antibody responses to certain infections are not protective. Both complement fixing classes of antibody and those that fix complement poorly have been shown to contain blocking activity. In the studies reported here, we found that the murine IgG3 subclass that fixes complement and promotes phagocytosis in the presence of complement components (31) had blocking activity in vivo. Our discovery of blocking mAbs to C. neoformans suggests a potential explanation for the inconsistent results obtained in protection experiments with polyclonal sera (32) (33) (34) . IgG3 is the major IgG isotype elicited in the mouse by T cell-independent type II antigens (35) , such as cryptococcal polysaccharide (36) . In addition, IgG3 antibodies bind with increased avidity because of cooperative Fc-Fc interactions after antigen binding (21, 22) . The fact that IgG3 anticryptococcal antibodies are both nonprotective and able to block antibody immunity raises the intriguing possibility that these antibodies could promote fungal infection and that the titer of IgG3 antibodies in polyclonal sera may explain the variable efficacy ofpolyclonal preparations administered passively (32, 33) or elicited by immunization with polysaccharide-protein conjugates (34) . If anticryptococcal antibodies with blocking activity occur in humans, isotype differences between HIV-positive and HIVnegative individuals could contribute to increased susceptibility to cryptococcal infection (37) .
Several mechanisms could explain the IgG3-mediated blocking activity. A straightforward competition for antigenic sites or a difference in antigenic density or accessibility is unlikely to explain this phenomenon, since we observed interference with antibodies that bind distinct as well as identical epitopes. For the 3E5 IgG3 and IgG1 pair, antigen density is presumably the same since they have identical variable regions. IgG3 antibodies may modify the structure or flexibility of the capsule, preventing effective opsonization by IgG1 and IgG2a. IgG3 may facilitate phagocytosis by effector cells that are not primed for killing, countering the protective effect of lgG1 and lgG2a. Finally, IgG3 immune complexes could conceivably alter the innate cytokine response to infection, thus suppressing cellmediated immunity.
Our results indicate that murine IgG3 antibodies to C. neoformans GXM are deleterious to the host by either enhancing infection or interfering with the function of protective antibodies. In contrast, mAbs of IgM, IgG2a, IgG2b, and IgA isotypes have all been shown to be protective (19, 38) . The ineffectiveness oflgG3 antibodies against C. neoformans contrasts with the effectiveness of this isotype against other encapsulated pathogens such as Streptococcus pneumoniae (39) . Our findings have important implications for the potential use of antibodies in the treatment and prevention of cryptococcal infection. Human correlates of the murine protective and nonprotective isotypes, if they exist, need to be identified and this information applied to vaccine design and the selection of antibodies for passive therapy.
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